Healthcare >> Analyst Interviews >> April 8, 2013

FDA Approvals Accelerate and Opportunities Arise in Hepatitis C Market

Brian Skorney is one of Robert W. Baird & Co.’s Senior Analysts covering biotechnology. Mr. Skorney has followed the sector for six years, most recently at Brean Murray Carret & Co. Prior to his career in equity research, Mr. Skorney worked in medical research. Mr. Skorney received a B.S. in biological sciences from the University of Notre Dame and an MBA in finance from the Stern School of Business at New York University. Profile
TWST: Can you begin with a brief introduction to your coverage, including some of the specific names you cover?

Mr. Skorney: I'm fairly new at Baird, so I'm kind of still in the